CCR1 and Parkinson disease: The use of CCR1 antagonists, such as BX471, provided beneficial effects that include improved control of PD symptoms, decreased neuroinflammation and activation of the NFkB pathway, as well as decreased infiltration of immune cells after MPTP-induced nigrostriatal degeneration.